Citius Pharmaceuticals (CTXR) Announces TenX Keane Shareholder Approval of Merger with Citius Oncology

Citius Pharmaceuticals, Inc. ("Citius Pharma" or the "Company") (Nasdaq: CTXR), a late-stage biopharmaceutical company dedicated to the development and commercialization of first-in-class critical care products, today announced that shareholders of TenX Keane Acquisition ("TenX") (Nasdaq: TENK), a publicly traded special purpose acquisition company, have voted to approve the previously announced business combination with Citius Pharma's oncology subsidiary. The newly combined public company will continue to trade on the Nasdaq stock exchange and is to be renamed Citius Oncology, Inc. ("Citius Oncology").

The transaction has been unanimously approved by the Board of Directors of both companies and Citius Pharma. Subject to certain contractual as well as customary closing conditions, the merger is expected to be completed in the coming weeks.

The transaction is expected to provide Citius Oncology with improved access to the public equity markets, support the commercialization of LYMPHIR, if approved, and position the company to explore additional targeted oncology opportunities.

"We look forward to closing this transaction in the coming weeks and unlocking and growing the value of our oncology asset," stated Leonard Mazur, Chairman and CEO of Citius Pharma.

You May Also Be Interested In

• Invitation Homes Inc. (INVH) Issues Acquisitions Update
• Cal-Maine Foods (CALM) Announces Strategic Investment in New Egg Products JV
• Regeneron (REGN): Libtayo Demonstrates Durable Survival Benefit at Five Years in Advanced Non-small Cell Lung Cancer